{"classes":[{"categories":[{"measurements":[{"groupId":"OG010","lowerLimit":"0.354","upperLimit":"1.59","value":"0.886"},{"groupId":"OG011","lowerLimit":"0.670","upperLimit":"0.968","value":"0.819"},{"groupId":"OG012","lowerLimit":"1.17","upperLimit":"1.17","value":"1.17"},{"groupId":"OG013","lowerLimit":"1.07","upperLimit":"1.24","value":"1.16"},{"groupId":"OG017","lowerLimit":"0.556","upperLimit":"0.650","value":"0.603"},{"groupId":"OG018","lowerLimit":"0.674","upperLimit":"1.60","value":"1.47"},{"groupId":"OG019","lowerLimit":"1.23","upperLimit":"2.54","value":"1.88"},{"groupId":"OG020","lowerLimit":"1.14","upperLimit":"2.82","value":"1.42"},{"groupId":"OG021","lowerLimit":"0.389","upperLimit":"0.838","value":"0.605"},{"groupId":"OG022","lowerLimit":"2.74","upperLimit":"6.18","value":"4.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"3"},{"groupId":"OG021","value":"4"},{"groupId":"OG022","value":"8"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"0"}],"units":"Participants"}],"title":"Cycle 1 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.50","upperLimit":"3.66","value":"2.77"},{"groupId":"OG001","lowerLimit":"1.30","upperLimit":"1.80","value":"1.58"},{"groupId":"OG002","lowerLimit":"1.36","upperLimit":"9.00","value":"1.95"},{"groupId":"OG003","lowerLimit":"0.834","upperLimit":"1.31","value":"1.07"},{"groupId":"OG004","lowerLimit":"1.04","upperLimit":"1.50","value":"1.36"},{"groupId":"OG007","lowerLimit":"0.430","upperLimit":"0.430","value":"0.430"},{"groupId":"OG009","lowerLimit":"0.309","upperLimit":"0.309","value":"0.309"},{"groupId":"OG014","lowerLimit":"0.810","upperLimit":"4.94","value":"1.73"},{"groupId":"OG015","lowerLimit":"0.698","upperLimit":"2.28","value":"1.50"},{"groupId":"OG016","lowerLimit":"0.461","upperLimit":"2.28","value":"0.981"},{"groupId":"OG027","lowerLimit":"0.992","upperLimit":"0.992","value":"0.992"},{"groupId":"OG028","lowerLimit":"0.236","upperLimit":"1.68","value":"1.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"3"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"1"},{"groupId":"OG028","value":"6"}],"units":"Participants"}],"title":"Cycle 1 day 2"},{"categories":[{"measurements":[{"groupId":"OG010","lowerLimit":"0.664","upperLimit":"1.31","value":"0.992"},{"groupId":"OG011","lowerLimit":"0.653","upperLimit":"0.785","value":"0.686"},{"groupId":"OG012","lowerLimit":"1.10","upperLimit":"1.10","value":"1.10"},{"groupId":"OG013","lowerLimit":"0.357","upperLimit":"2.57","value":"1.16"},{"groupId":"OG017","lowerLimit":"0.476","upperLimit":"0.828","value":"0.652"},{"groupId":"OG018","lowerLimit":"1.96","upperLimit":"5.61","value":"3.58"},{"groupId":"OG019","lowerLimit":"0.391","upperLimit":"0.422","value":"0.407"},{"groupId":"OG020","lowerLimit":"0.396","upperLimit":"1.01","value":"0.854"},{"groupId":"OG021","lowerLimit":"0.477","upperLimit":"1.78","value":"0.782"},{"groupId":"OG022","lowerLimit":"2.10","upperLimit":"3.62","value":"2.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"3"},{"groupId":"OG021","value":"4"},{"groupId":"OG022","value":"3"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"0"}],"units":"Participants"}],"title":"Cycle 1 day 8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0556","upperLimit":"0.0556","value":"0.0556"},{"groupId":"OG001","lowerLimit":"0.185","upperLimit":"0.335","value":"0.307"},{"groupId":"OG002","lowerLimit":"0.214","upperLimit":"0.222","value":"0.218"},{"groupId":"OG003","lowerLimit":"0.291","upperLimit":"0.291","value":"0.291"},{"groupId":"OG004","lowerLimit":"0.243","upperLimit":"0.314","value":"0.278"},{"groupId":"OG006","lowerLimit":"0.712","upperLimit":"8.93","value":"4.82"},{"groupId":"OG007","lowerLimit":"0.242","upperLimit":"0.242","value":"0.242"},{"groupId":"OG008","lowerLimit":"0.513","upperLimit":"1.000","value":"0.756"},{"groupId":"OG009","lowerLimit":"0.560","upperLimit":"1.65","value":"1.14"},{"groupId":"OG014","lowerLimit":"0.0733","upperLimit":"1.01","value":"0.544"},{"groupId":"OG015","lowerLimit":"0.393","upperLimit":"1.24","value":"0.744"},{"groupId":"OG027","lowerLimit":"0.978","upperLimit":"0.978","value":"0.978"},{"groupId":"OG028","lowerLimit":"0.856","upperLimit":"1.36","value":"1.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"1"},{"groupId":"OG028","value":"3"}],"units":"Participants"}],"title":"Cycle 1 day 9"},{"categories":[{"measurements":[{"groupId":"OG022","lowerLimit":"0.640","upperLimit":"15.9","value":"4.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"6"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"0"}],"units":"Participants"}],"title":"Cycle 1 day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"3"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"3"},{"groupId":"OG021","value":"4"},{"groupId":"OG022","value":"8"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"1"},{"groupId":"OG028","value":"6"}],"units":"Participants"}],"description":"Plasma concentrations of AMG 176 were determined using a validated assay. Noncompartmental analysis was performed for estimation of PK parameters. Concentrations below the LLOQ of 5.00 ng/mL were set to zero before data analysis. Clearance was calculated as Dose/ AUC0-144 for Parts 1A, 3A, and 4; and as Dose/AUC0-168 for Parts 1B, 3 (Cohort 4 only) 3B, 3C, and 3D.","dispersionType":"Full Range","groups":[{"description":"Participants with MM received AMG 176 Dose A BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG000","title":"Part 1A Cohort 1 (MM): AMG 176 Dose A BIW"},{"description":"Participants with MM received AMG 176 Dose B IV BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG001","title":"Part 1A Cohort 2 (MM): AMG 176 Dose B BIW"},{"description":"Participants with MM received AMG 176 Dose C BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG002","title":"Part 1A Cohort 3 (MM): AMG 176 Dose C BIW"},{"description":"Participants with MM received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG003","title":"Part 1A Cohort 4 (MM): AMG 176 Dose D BIW"},{"description":"Participants with MM received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG004","title":"Part 1A Cohort 5 (MM): AMG 176 Dose E BIW"},{"description":"Participants with MM received AMG 176 Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG005","title":"Part 1A Cohort 6 (MM): AMG 176 Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG006","title":"Part 1A Cohort 7 (MM): AMG 176 Dose E Then Dose F BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG007","title":"Part 1A Cohort 8 (MM): AMG 176 Dose E Then Dose G BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG008","title":"Part 1A Cohort 9 (MM): AMG 176 Dose E Then Dose H BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG009","title":"Part 1A Cohort 10 (MM): AMG 176 Dose E Then Dose I BIW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG010","title":"Part 1B Cohort 1 (MM): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG011","title":"Part 1B Cohort 2 (MM): AMG 176 Dose E Then Dose G QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose H QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG012","title":"Part 1B Cohort 3 (MM): AMG 176 Dose E Then Dose H QW"},{"description":"Participants with MM received AMG 176 Dose E in cycle 1 week 1, then received Dose I QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG013","title":"Part 1B Cohort 4 (MM): AMG 176 Dose E Then Dose I QW"},{"description":"Participants with AML received AMG 176 Dose D BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG014","title":"Part 3A Cohort 1 (AML): AMG 176 Dose D BIW"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG015","title":"Part 3A Cohort 2 (AML): AMG 176 Dose E BIW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F BIW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG016","title":"Part 3A Cohort 3 (AML): AMG 176 Dose E Then Dose F BIW"},{"description":"Japanese participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG017","title":"Part 3A Cohort 4 (Japanese Participants With AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG018","title":"Part 3B Cohort 1 (AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG019","title":"Part 3B Cohort 2 (AML): AMG 176 Dose E Then Dose F QW"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG020","title":"Part 3B Cohort 3 (AML): AMG 176 Dose E Then Dose G QW"},{"description":"Japanese participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle.","id":"OG021","title":"Part 3C Cohort 1 (Japanese Participants With AML): AMG 176 Dose E QW"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 200 mg itraconazole QD for 7 days in week 1.","id":"OG022","title":"Part 3D Cohort 1 (AML): AMG 176 Dose D QW + Itraconazole"},{"description":"Participants with AML received AMG 176 Dose D QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG023","title":"Part 4 Cohort 1 (AML): AMG 176 Dose D QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG024","title":"Part 4 Cohort 2 (AML): AMG 176 Dose E QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose F QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG025","title":"Part 4 Cohort 3 (AML): AMG 176 Dose E Then Dose F QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G QW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG026","title":"Part 4 Cohort 4 (AML): AMG 176 Dose E Then Dose G QW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG027","title":"Part 4 Cohort 5A (AML): AMG 176 Dose E BIW + Azacitidine"},{"description":"Participants with AML received AMG 176 Dose E in cycle 1 week 1, then received Dose G BIW. AMG 176 was administered as an IV infusion in a 4-week cycle. They also received 75 mg/m\\^2 azacitidine SC or IV QD for 7 days in week 1.","id":"OG028","title":"Part 4 Cohort 5B (AML): AMG 176 Dose E the Dose G BIW + Azacitidine"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set included all participants who had received at least 1 dose of AMG 176 and had at least 1 PK sample collected. Participants with data available at each time point are presented.","reportingStatus":"POSTED","timeFrame":"Parts 1B, 3B, 3C, 3A (cohort 4) Cycle 1: day 1 pre, EOI, 1, 2, 3, 5, 7 hrs EOI, day 8 pre, EOI; Part 3D also days 9, 15 pre and EOI; Parts 1A, 3 (except cohort 4), 4: also day 2 pre, EOI, 1, 2, 3, 5, 7 hrs EOI, day 9 pre and EOI","title":"Clearance (CL) of AMG 176","type":"PRIMARY","unitOfMeasure":"mL/hr/m^2"}